Arvinas (ARVN) · ARV-806
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2026
initial clinical data in patients with solid tumors harboring KRAS G12D mutations in 2026
· filed · SEC filing
After
Stated timing: second half of 2026
KRAS G12D mutations. ◦ Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/ARVN-arv-806-2026-08-04, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/ARVN-arv-806-2026-08-04
Arvinas (ARVN) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.